(Q26997059)

non-alcoholic fatty liver

inferred from title

1 reference

1 reference

Athyros VG

1

1 reference

Tziomalos K

2

1 reference

Katsiki N

3

1 reference

Doumas M

4

1 reference

Karagiannis A

5

1 reference

Mikhailidis DP

6

1 reference

language of work or name

1 reference

14 June 2015

1 reference

World Journal of Gastroenterology

published in

1 reference

volume

21

1 reference

issue

22

1 reference

page(s)

6820-34

1 reference

Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning?

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Mechanisms of arterial calcifications and consequences for cardiovascular function

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH)

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Nonalcoholic fatty liver disease and vascular disease: state-of-the-art.

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Cardiovascular disorders in the context of non-alcoholic Fatty liver disease: a literature review

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Long-term follow-up of patients with NAFLD and elevated liver enzymes

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Association between non-alcoholic fatty liver disease and arterial stiffness in the non-obese, non-hypertensive, and non-diabetic young and middle-aged Chinese population

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

CKD and nonalcoholic fatty liver disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Nonalcoholic fatty liver disease and cardiovascular disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Halting arterial aging in patients with cardiovascular disease: hypolipidemic and antihypertensive therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Treating Arterial Stiffness in Young and Elderly Patients with the Metabolic Syndrome

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Chronic kidney disease and nonalcoholic Fatty liver disease-is there a link?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Chronic kidney disease and associated mortality after liver transplantation--a time-dependent analysis using measured glomerular filtration rate.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Metabolic syndrome and non-cardiac vascular diseases: an update from human studies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Role of arterial stiffness in cardiovascular disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

The role of statins in the treatment of type 2 diabetes mellitus: an update

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Extrahepatic complications of nonalcoholic fatty liver disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Novel therapeutic targets for nonalcoholic fatty liver disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Sagittal abdominal diameter is a more independent measure compared with waist circumference to predict arterial stiffness in subjects with type 2 diabetes--a prospective observational cohort study.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Hyperuricaemia: more than just a cause of gout?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

The relationship between arterial stiffness and nonalcoholic fatty liver disease.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Decreased survival of subjects with elevated liver function tests during a 28-year follow-up.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Anti-inflammatory drugs and statins for arterial stiffness reduction

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Chronic kidney disease in Japan

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Pathogenesis and management issues for non-alcoholic fatty liver disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Hepatic histology in obese patients undergoing bariatric surgery

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Chronic kidney disease as cause of cardiovascular morbidity and mortality

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Long term prognosis of fatty liver: risk of chronic liver disease and death.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Epidemiology of cardiovascular risk in patients with chronic kidney disease.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Non-alcoholic steatohepatitis (NASH): where are we now and where are we going?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Non-alcoholic fatty liver disease is associated with progression of arterial stiffness

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Mortality from chronic liver diseases in diabetes

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Effects of atorvastatin on arterial stiffness in chronic kidney disease: a randomised controlled trial

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.

31 May 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Non-alcoholic fatty liver disease fibrosis score and FIB-4 scoring system could identify patients at risk of systemic complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Initiative for a new diabetes therapeutic approach in a Mediterranean country: the INDEED study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Impact of non-alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Relationship between serum gamma-glutamyltransferase and chronic kidney disease in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Relationship of serum bilirubin concentrations to kidney function and albuminuria in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Plasma fetuin-A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Dysregulation of hepatic fatty acid metabolism in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Chronic kidney disease (CKD) and NAFLD: time for awareness and screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Association of fatty liver disease with nonfatal cardiovascular events in patients undergoing maintenance hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Statins and nonalcoholic fatty liver disease: a bright future?

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Are statins 'IDEAL' for non-alcoholic fatty liver disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Statins and renal function in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Uric acid, chronic kidney disease and type 2 diabetes: a cluster of vascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Increased whole blood viscosity associated with arterial stiffness in patients with non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Effects of rosuvastatin vs. simvastatin/ezetimibe on arterial wall stiffness in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Inhibition of inducible nitric oxide synthesis ameliorates liver ischemia and reperfusion injury induced transient increase in arterial stiffness

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Dose-dependent effects of short term atorvastatin treatment on arterial wall properties and on indices of left ventricular remodeling in ischemic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Metabolic syndrome and arterial stiffness: the past, the present and the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I22.6820

Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

The prevalence and etiology of elevated aminotransferase levels in the United States

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4462722

Hyperuricemia as a risk factor for cardiovascular disease

28 November 2018

1 reference

12 December 2020

Yes! Statins can be given to liver patients

1 reference

12 December 2020

Association between whole blood viscosity and arterial stiffness in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Ev

1 reference

12 December 2020

Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options

1 reference

12 December 2020

Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness

1 reference

12 December 2020

Arterial stiffness: a novel cardiovascular risk factor in kidney disease patients

1 reference

12 December 2020

The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

1 reference

12 December 2020

Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property

1 reference

12 December 2020

Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels

1 reference

12 December 2020

Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease

1 reference

12 December 2020

A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients

1 reference

12 December 2020

Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease

1 reference

12 December 2020

Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999

1 reference

12 December 2020

Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance

1 reference

12 December 2020

Association of uric acid levels with components of metabolic syndrome and non-alcoholic fatty liver disease in overweight or obese children and adolescents

1 reference

12 December 2020

Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study

1 reference

12 December 2020

Effects of increased systemic inflammation and central obesity on arterial stiffness in patients with nonalcoholic fatty liver disease

1 reference

12 December 2020

Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease

1 reference

12 December 2020

Thinking beyond traditional cardiovascular risk factors: the role of arterial stiffness in targeting residual risk

1 reference

12 December 2020

Identifiers

DOI

10.3748/WJG.V21.I22.6820

1 reference

1 reference

1 reference

PubMed publication ID

26078558

1 reference